A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis.

Carlo LazzaroCécile van SteenGiorgio GhirelliMatteo SacchiDario SistoMaurizio UvaLuigi VaranoLuigi Angelillo

Published in: Expert review of pharmacoeconomics & outcomes research (2023)

STN1013001 is potentially highly cost-effective and strongly dominant vs. Latanoprost for OAG/OHT+OSD patients from the INHS perspective. These findings should be re-assessed using the data from the ongoing Phase III trial (NCT04133311) comparing the efficacy and safety of STN1013001 vs. Latanoprost and with future real-world CUAs upon the availability of STN1013001 on the Italian market.

Keyphrases

phase iii
clinical trial
open label
end stage renal disease
phase ii
blood pressure
ejection fraction
newly diagnosed
chronic kidney disease
double blind
study protocol
electronic health record
placebo controlled
machine learning
big data
optical coherence tomography